ZURICH, Aug 27 - The following are some of the main factors
expected to affect Swiss stocks on Thursday:
GIVAUDAN GIVN.VX
The Swiss flavours and fragrance maker on Thursday cut its
five-year organic sales growth target to 4 to 5 percent from its
previous target of 4.5 to 5.5 percent. The Geneva-based firm
said it would target 12 to 17 percent free cash flow as a
percentage of sales by 2020, from the 14 to 16 percent target
set for 2015.
For more click on GIVN.VX
ROCHE HOLDING AG ROG.VX
The Swiss drugmaker says a combination of its Cotellic and
Zelboraf medicines were approved in Switzerland for the
treatment of patients with advanced melanoma.
For more click on ROG.VX
COMPANY STATEMENTS CPR-CH
* Swiss Prime Site SPSN.S said its first-half profit
surged 39 percent to 191 million Swiss francs. SPSN.S
* Sika Holding AG SIK.VX said it opened its fourth
production site in Russia. SIK.VX
* Baloise Holding AG BALN.VX said first-half net income
attributable to shareholders fell to 248.7 million francs, from
349.9 million francs. BALN.VX
* Valora Holding AG VALN.S posted a net loss of 26.3
million francs in the first half. It said it was "well on its
way" to fulfilling its full-year guidance. VALN.S
* Liechtensteinische Landesbank LLB.S said group net
profit rose in the first half to 44.2 million francs, up 9
percent from the previous year. It expects net profit for the
current year to be at last year's levels. LLB.S
* Accu Holding AG ACUN.S said it saw a slightly lower
result, taking into account seasonal effects in the second half
of the year. ACUN.S
* Repower REPI.S said it expected a net loss substantially
higher than in 2014. It posted a first-half net loss of 108
million Swiss francs. REPI.S
* Compagnie Financiere Tradition CFT.S said first-half
operating profit advanced to 35.9 million francs. CFT.S
* Perrot Duval PEDU.S said first-half net profit after
taxes fell to 0.1 million francs. PEDU.S
* Actelion ATLN.VX announced it would share data from a
Phase III study on its investigational pulmonary arterial
hypertension drug selexipag at an upcoming cardiology congress
in London. The company said it would also present further
information on macitentan at the congress. ATLN.VX
ECONOMY M-CH
Swiss industry orders for the second quarter due at 0715 GMT
(Reporting by Zurich newsroom)
((+41 58 306 7336)(zurich.newsroom@thomsonreuters.com))
((For Top News in a multimedia Web format on Eikon visit:
https://emea1.views.cp.extranet.thomsonreuters.biz/Explorer/NEWSxTOPNEWS.aspx?group=SP_GROUP_001&page=SP_PAGE_001&pageName=FrontPage
FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
Daily Swiss stock market report in German................ .SDE
All SMI constituent stocks............................ 0#.SSMI
News on major Swiss stock price moves.................. CH-HOT
FTSE Eurotop 300 index................................ .FTEU3
DJ STOXX index........................................ .STOXX
Top 10 STOXX sectors............................. .PGL.STOXXS
Top 10 EUROSTOXX sectors........................ .PGL.STOXXES
Top 10 Eurotop 300 sectors....................... .PGL.FTEU3S
Top 25 European pct gainers... .PG.PEUR , losers... .PL.PEUR
Swiss mid-cap index .SSMI SMI futures 0#SMI:
Swiss all-share index .SSHI Market statistics CH/STATS1
Swiss market digest .AD.S Sector overview CH/SECTOR1
All Swiss news CH Swiss diary CH/DIARY
Swiss research news CH-RCH Virt-x sectors VX/SECTOR1
All equity news E Virt-x price index .VMIP
INTERNET ADDRESSES: Virt-x www.virt-x.com
Swiss Exchange www.swx.ch/
Eurex www.eurexchange.com
STOXX Ltd www.stoxx.com
SPEED GUIDES: VX/EQUITY EQUITY EQUITY/NEWS1 EUR/EQUITY
SWITZERLAND REUTERS ))
Keywords: MARKETS SWISS STOCKS/
Recent news on Liechtensteinische Landesbank Aktiengesellschaft